Expert: Central enterprises will continue to recruit in A-shares. On the evening of December 9, Huada Jiutian, a domestic EDA leader, announced that China Electronic Information Industry Group Co., Ltd. will become the actual controller of the company. So far, the number of A-share listed companies "incorporated" by central enterprises reached 10 in 2024. The end of 2024 is an important node for central enterprises to optimize the layout of listed platforms. The Work Plan for Improving the Quality of Listed Companies Controlled by Central Enterprises previously issued by the State-owned Assets Supervision and Administration Commission of the State Council made it clear that the adjustment and revitalization of the listing platform should be basically completed by the end of 2024, and it is supported to revitalize through absorption and merger, asset restructuring and cross-market operation, or to withdraw through free transfer and equity transfer, so as to further focus on the main business and advantageous areas. Looking forward to the next layout rhythm of central enterprises in the capital market, many experts interviewed by reporters believe that the pace of "recruiting" of central enterprises in A shares will continue. In the coming period, the cases of central enterprises strengthening their main business through capital operation and giving play to their strategic support and industrial leading functions will be on the rise. (shanghai securities news)More support policies for specialization and innovation are brewing. According to the data of the Ministry of Industry and Information Technology, up to now, China has cultivated a total of 14,600 "little giant" enterprises with specialization and innovation, and more than 140,000 small and medium-sized enterprises with specialization and innovation. Over 80% of the "Little Giant" enterprises are located in strategic emerging industrial chains such as integrated circuits and aerospace, and the number of enterprises in future industry-related fields such as artificial intelligence and low-altitude economy is nearly 5,000. The reporter was informed that the relevant departments will study and formulate guidance on building a mechanism to promote the development and growth of specialized and innovative small and medium-sized enterprises, issue guidance on cultivating high-quality enterprises, continue to increase support for the cultivation of specialized and innovative small and medium-sized enterprises, and promote the "expansion, quality improvement and strong chain" of specialized and innovative groups. (Economic Information Daily)More than 700 listed companies have announced the replacement of the audit institutions in 2024. According to incomplete statistics, since the beginning of this year, the number of listed companies planning to replace the accounting firms in 2024 has exceeded 700. Among them, the number of listed companies that intend to change accounting firms in October and November is 248 and 200 respectively. Looking back at the "exchange tide", three phenomena stand out: First, in order to improve the quality and ability of capital market intermediaries, the supervision of accounting firms by the regulatory authorities has been significantly enhanced. Based on the principle of prudence, listed companies collectively cancel the contract with the "problem institute"; Second, under the heavy penalty, more and more accountants choose to change their firms to practice, while listed companies choose to change their firms instead of accountants; Third, listed companies employ audit institutions through competitive negotiation, public bidding, invitation bidding, etc. In the bidding process, in order to attract more customers and increase the signing rate, the phenomenon of audit institutions reducing prices has increased. (Securities Daily)
In 2024, the number of cases of dengue fever in Brazil exceeded 6.76 million. On December 10, local time, according to the latest data from the Brazilian Ministry of Health, this year, the number of suspected and confirmed cases of dengue fever in Brazil rose to 6,763,743, and the number of deaths rose to 5,950, with another 1,091 deaths to be verified. In 2024, the number of cases of dengue fever infection in Brazil reached a record high since the country's epidemic record, which was three times that of 2023. The death toll of dengue fever has also reached a record high, four times that of 2023. The regions with the highest infection rates are federal capital territory, minas gerais, Balana and Sã o Paulo.The latest monitoring report released by the World Bank shows that Lebanon's GDP will drop by 6.6% in 2024. The latest Lebanon economic monitoring report released by the World Bank on the 10th shows that the real GDP of Lebanon will drop by 6.6% in 2024 due to the influence of lebanon war. According to the report, the large-scale displacement, destruction and the reduction of personal consumption caused by the conflict have had a devastating impact on Lebanon's economy and exacerbated the country's macroeconomic challenges. The report emphasizes that after the upgrading of lebanon war in September this year, Lebanese key industries, including tourism, have been seriously affected.Nikkei futures opened down 95 points at 39,290 on the Singapore Stock Exchange.
Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Monetary policy has turned to "moderate easing", and experts say that it is expected to make greater efforts to lower the RRR and cut interest rates. The the Political Bureau of the Communist Party of China (CPC) Central Committee meeting held on December 9 changed the orientation of monetary policy from "steady" to "moderate easing" next year. Experts said that under the orientation of "moderate easing", the monetary policy space was further opened. In terms of total amount, it is more reasonable and sufficient to maintain liquidity; In terms of price, appropriately reducing the financing cost will better reflect the effectiveness of monetary policy. Next year, even greater RRR cuts and interest rate cuts can be expected. In addition to lowering the RRR and cutting interest rates, experts said that structural monetary policy tools, buying government bonds, open market buyout reverse repurchase and other operations are expected to continue to expand the scale, increase the frequency of use, and continuously enhance the effectiveness and pertinence of monetary policy. (CSI)Xie Yunliang, macro chief analyst of Cinda Securities, said that historically, the establishment of a "moderately loose" policy orientation needs to meet two major conditions, namely, the domestic pressure to stabilize prices is high and the foreign Federal Reserve is in a loose cycle. At present, it is judged that both situations may exist next year.
Strategy guide 12-14
Strategy guide 12-14